Via practica 2/2009
Overview of results in selected in pharmacoeconomic study of ACEi ramipril
Ramipril belongs to the group of most frequent ACE inhibitors. HOPE study came with breakthrough results compared to options offered by different ACE inhibitors. Treatment with ramipril is considered to be cost-effective also in the German’s local conditions.
Keywords: ramipril, ICER, effectiveness
